Skip to search
Skip to main content
Back to Search
Start Over
A comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of patients with high risk, Ph-pos, chronic myeloid leukemia. An ELN Study
Authors :
Baccarani, M. Rosti, G. Castagnetti, F. Haznedaroglu, I. Porkka, K. Abruzzese, E. Alimena, G. Amabile, M. Boström, H. Hjorth Hansen, H. Kairisto, V. Levato, L. Martinelli, G. Nagler, A. Lanng Nielsen, J. Ozbek, U. Palandri, F. Palmieri, F. Pane, F. Rege Cambrin, G. Russo, Domenico Specchia, G. Testoni, N. Weiss Bjerrum, O. Saglio, G. Simonsson, B.
Publication Year :
2009
Details
Language :
English
Database :
OpenAIRE
Accession number :
edsair.od......3662..fa23dec7cbd5c6169d53e47e6533df6e